Cyclizine

USDailyMed:Fexofenadine AU:B2 R06AX26(WHO) AU:S2(Pharmacy medicine) / S4BR:OTC(Over the counter)CA:OTCUK:P (Pharmacy medicines) / P/ GSLUS:OTC/ Rx-only (±)-4-[1-Hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]-butyl]-α, α-dimethyl benzeneacetic acid 83799-24-0Y 3348 4819 DB00950Y 3231Y E6582LOH6V D07958Yas HCl:D00671Y CHEBI:5050Y ChEMBL914Y DTXSID00861411 Interactive image O=C(O)C(c1ccc(cc1)C(O)CCCN2CCC(CC2)C(O)(c3ccccc3)c4ccccc4)(C)C InChI=1S/C32H39NO4/c1-31(2,30(35)36)25-17-15-24(16-18-25) 29(34)14-9-21-33-22-19-28(20-23-33)32(37, 26-10-5-3-6-11-26)27-12-7-4-8-13-27/h3-8, 10-13,15-18,28-29,34,37H,9,14,19-23H2,1-2H3,(H,35,36)NKey:RWTNPBWLLIMQHL-UHFFFAOYSA-NY Fexofenadine, sold under the brand nameAllegraamong others,is anantihistaminemedication used in the treatment ofallergysymptoms such asallergic rhinitisandurticaria. Therapeutically, fexofenadine is aselectiveperipheralH1blocker. It is classified as a second-generation antihistamine because it is less able to pass theblood–brain barrierand cause sedation, compared to first-generation antihistamines. It was patented in 1979 and came into medical use in 1996.Fexofenadine is a therapeutic alternative on theWorld Health Organization's List of Essential Medicines.Fexofenadine has been manufactured in generic form since 2011.In 2023, it was the 219th most commonly prescribed medication in the United States, with more than 1million prescriptions.